Short answer
Thermo Fisher Scientific (TMO) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $12.1B (up 9.1% year over year) with net income of $1.7B.
Q3 2026 key financials · XBRL
- Revenue
- $12.1B
- +9.1% YoY · +1.2% QoQ
- Net income
- $1.7B
- +6.5% YoY · −0.9% QoQ
- Operating margin
- 18.6%
- EPS (diluted)
- $4.65
- +8.9% YoY · −0.4% QoQ
Source: XBRL data from the Thermo Fisher Scientific (TMO) Q3 2026 10-Q on SEC EDGAR. USD.
Thermo Fisher Scientific Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $12,137M, up from $11,122M YoY; Laboratory Products and Biopharma Services led contributions
- GAAP operating margin 18.6% vs 17.4%; adjusted margin 24.5% vs 23.3%
- Best segment: Laboratory Products and Biopharma Services revenue $6,863M vs $5,970M, margin 15.5% vs 14.5%
- Worst segment: Specialty Diagnostics revenue $1,098M vs $1,174M; margin 31.0% vs 27.4%
- Cash $5,461M vs $9,852M; operating cash flow $5,867M, free cash flow $4,618M, acquisitions $8.88B
Risk Factors
- No material changes identified from the December 31, 2025 Form 10-K
- Carried-forward risks remain detailed in the company’s 2025 Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Thermo Fisher Scientific quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.